Metformin May Boost Longevity by 30%, New Liver & Eye Breakthroughs in Diabetes

Diabetes care is in the spotlight again. Today brings a mix of hope and caution. A common drug shows promise for living longer. Another fights fatty liver disease. Yet, some weight-loss and glucose-control therapies carry eye risks. Read on to discover what’s new, why it matters, and how you can get cash for unused diabetic supplies.

Metformin and Exceptional Longevity

A study of 438 postmenopausal women with type 2 diabetes found those on metformin were 30% more likely to live past 90. Researchers followed participants for 14 to 15 years. They compared metformin to sulfonylurea treatments.

Metformin targets multiple aging pathways. It may slow biological aging and cut age-related disease risk. This aligns with the geroscience hypothesis, which suggests aging can be slowed by drugs.

But not all news on metformin is positive. A separate analysis of 240,000 type 2 diabetes patients showed a 15% higher risk of neovascular age-related macular degeneration (nvAMD) in metformin users (hcplive.com). A rise in vascular endothelial growth factor (VEGF) may drive that risk.

Why it matters
Knowing both sides helps you and your doctor weigh benefits and risks. Metformin may extend life, but plan regular eye exams if you’re on it.

New Diabetes Types and Early Biomarkers

Health experts now recognize type 5 diabetes, or malnutrition-related diabetes mellitus (MRDM). It stems from early-life undernutrition, especially protein-energy malnutrition. That can harm pancreas development. It affects people in parts of Africa, Asia, and Latin America, often emerging in teens or young adults (draxe.com).

Type 5 isn’t autoimmune like type 1, nor purely lifestyle-based like type 2. Management focuses on balanced meals, oral meds, and preventing further malnutrition. Early detection can help control blood sugar and protect organs.

Meanwhile, the triglyceride-glucose (TyG) index is gaining attention as a cardiovascular risk biomarker in type 2 diabetes. A study in Scientific Reports linked higher TyG scores to subtle right ventricular dysfunction. Monitoring TyG could help doctors spot heart problems early.

Breakthrough in Fatty Liver Disease Treatment

Fatty liver disease, or metabolic dysfunction-associated steatohepatitis (MASH), affects many with diabetes. Dapagliflozin, a diabetes drug, shows great promise.

Three trials, including one in DJournal and another in The BMJ (insidenova.com), found:

• Nearly 25% of patients saw complete resolution of fatty liver.
• 45% had less liver scarring versus 20% on placebo.
• Dapagliflozin was well tolerated with no major side effects.

Why it matters
Fatty liver can lead to cirrhosis, liver failure, and heart disease. A safe, effective diabetes drug could simplify treatment and improve outcomes.

Weighing GLP-1 Therapies: Eye Safety Concerns

GLP-1 receptor agonists help with blood sugar and weight loss. But new data raise red flags about long-term eye health.

• A JAMA Ophthalmology study in Canada reviewed 139,002 diabetes patients. Those on GLP-1s were twice as likely to develop neovascular age-related macular degeneration (nAMD) (fiercepharma.com).
• A separate large analysis of over 1 million Ontario residents found GLP-1 users had double the nAMD risk, rising to three times after 30 months (theguardian.com).
• Another report linked GLP-1 RA drugs to higher rates of diabetic retinopathy (source).

Why it matters
If you’re on or considering GLP-1 therapy, ask your doctor about eye exams. Early detection of macular degeneration or retinopathy can save vision.

Adjunct Treatments and Comparative Studies

Clinicians keep testing ways to improve diabetes outcomes with existing drugs:

• Dapagliflozin in Youth with Type 1 Diabetes: The 22-week ATTEMPT trial showed dapagliflozin plus insulin cut HbA1c by 0.47% and boosted time-in-range by 9% (nature.com).
• Rosuvastatin Dosing: A 12-week trial found daily and alternate-day rosuvastatin both effectively cut LDL cholesterol in diabetic dyslipidemia, with similar safety (cureus.com).
• Statins and Depression: Simvastatin added to escitalopram showed no extra benefit for depression in obese patients (drugtopics.com).
• Prostate Cancer Link: An international study suggests some diabetes drugs may lower prostate cancer recurrence rates, opening doors for future research (source).

Community & Prevention: Food, Funds & Awareness

Beyond meds, lifestyle and support matter:

• Bean Power for Pre-Diabetes: A 12-week trial found that 1 cup of chickpeas or black beans daily lowered inflammation and improved cholesterol in pre-diabetes (sci.news).
• Grocery Store Tours: Dietitians at Hackensack Health and ShopRite offer free monthly tours to teach healthy shopping and simple food swaps (newswise.com).
• Lack of Awareness: One in three young adults don’t know they have high blood pressure, and two in five miss their diabetes diagnosis (medicalxpress.com). Regular check-ups are key.
• Hospital Excellence: Three Long Island hospitals earned ADA-Leapfrog recognition for top inpatient diabetes care (libn.com).
• Fundraisers Honored: The Tour de Cure celebrated champion fundraisers at the Rochester Yacht Club, raising vital research dollars (13wham.com).

Sell Your Unused Diabetic Supplies for Cash

Got unopened test strips, lancets, or CGM sensors gathering dust? DiabeticSupplies.Online pays top dollar. Mail in your supplies and get money fast. It’s safe, simple, and helps reduce waste.

FAQ – People Also Ask